

Department of Planning and Budget 2024 Session Fiscal Impact Statement

1. Bill Number: HB760

House of Origin	<input checked="" type="checkbox"/>	Introduced	<input type="checkbox"/>	Substitute	<input type="checkbox"/>	Engrossed
Second House	<input type="checkbox"/>	In Committee	<input type="checkbox"/>	Substitute	<input type="checkbox"/>	Enrolled

2. Patron: Delaney

3. Committee: Labor and Commerce

4. Title: Health insurance; cost-sharing payments for insulin and diabetes equipment and supplies; limit.

5. Summary: Decreases the cap on the cost-sharing payment that a covered person is required to pay for a covered prescription insulin drug from \$50 to \$35 for a 30-day supply of the prescription insulin drug and provides such cap is an aggregate cap that applies in situations where the covered person is prescribed more than one insulin drug. The bill also establishes such an aggregate cap of \$35 for a 30-day supply of diabetes equipment and supplies.

6. Budget Amendment Necessary: No.

7. Fiscal Impact Estimates: Preliminary – see Item 8.

8. Fiscal Implications: According to the Department of Human Resource Management, the proposed legislation is not expected to have a fiscal impact on the state health insurance plan.

According to the State Corporation Commission, qualified health plans (QHPs) sold through the Health Benefit Exchange are not impacted by the provisions of this bill. Section 38.2-6506 A 1, Code of Virginia, states that if services are identified in addition to the ones contained in the state's Benchmark Plan, QHPs sold through the Exchange would not be required to cover these services; therefore, the proposed legislation would not require defrayal of costs to insurers.

9. Specific Agency or Political Subdivisions Affected: Department of Human Resource Management and State Corporation Commission

10. Technical Amendment Necessary: No.

11. Other Comments: None.